Seroprevalence of SARS-CoV-2 Infection and Adherence to Preventive Measures in Cuenca, Ecuador, October 2020, a Cross-Sectional Study.

COVID-19 Ecuador IgG antibodies IgM antibodies PCR test adherence prevalence preventive measures

Journal

International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455

Informations de publication

Date de publication:
27 04 2021
Historique:
received: 04 03 2021
revised: 19 04 2021
accepted: 23 04 2021
entrez: 30 4 2021
pubmed: 1 5 2021
medline: 5 5 2021
Statut: epublish

Résumé

A door-to-door survey was organised in Cuenca, Ecuador, to determine the prevalence of COVID-19 infection and adherence of the population to COVID-19 preventive measures. A total of 2457 persons participated in the study; 584 (23.7%) reported having experienced at least one flu-like symptom since the onset of the pandemic. The maximum SARS-CoV-2 seroprevalence in Cuenca was 13.2% (CI: 12-14.6%) (IgM or IgG positive). Considering PCR confirmed infections, the prevalence was 11% (CI: 10-12.4%). There was no significant difference in seroprevalence between rural and urban areas. Participants aged 35-49 years old, living with a COVID-19 positive person, at least six people in a household, physical contact with someone outside the household, a contact with a person outside the home with flu-like symptoms, using public transport, and not having enough resources for living, significantly increased the odds for SARS-CoV-2 seropositivity. Overall, there was good adherence to COVID-19 preventive measures. Having known someone who tested positive for COVID-19, having a primary or secondary level of education, and having enough resources for living, significantly increased the odds for higher adherence. In conclusion, despite good overall adherence of the population of Cuenca with COVID-19 preventive measures, our study suggests high ongoing COVID-19 transmission in Cuenca, particularly in certain parishes. Prevention should not only focus on behavioural change, but on intensified testing strategies in demographical risk groups.

Identifiants

pubmed: 33925680
pii: ijerph18094657
doi: 10.3390/ijerph18094657
pmc: PMC8124135
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : VLIRUOS (Flemish Interuniversity Council for University Development Cooperation)
ID : NAP

Références

EClinicalMedicine. 2021 Apr;34:100801
pubmed: 33817611
Math Biosci. 2020 Nov;329:108452
pubmed: 32818515
Clin Microbiol Rev. 2020 Jun 24;33(4):
pubmed: 32580969
Science. 2021 Jan 15;371(6526):288-292
pubmed: 33293339
Infect Control Hosp Epidemiol. 2020 Jun;41(6):746-747
pubmed: 32192550
Lancet. 2020 Aug 22;396(10250):535-544
pubmed: 32645347
Clin Infect Dis. 2020 Jul 27;:
pubmed: 32717052
Int J Environ Res Public Health. 2021 Jan 26;18(3):
pubmed: 33530538
Int J Infect Dis. 2020 Dec;101:334-341
pubmed: 33039614
J Korean Med Sci. 2020 Jun 15;35(23):e220
pubmed: 32537955
J Korean Med Sci. 2020 May 18;35(19):e182
pubmed: 32419400
Nat Med. 2021 Jan;27(1):94-105
pubmed: 33097835

Auteurs

David Acurio-Páez (D)

Faculty of Medical Science: Universidad de Cuenca, 010202 Cuenca, Ecuador.

Bernardo Vega (B)

Faculty of Medical Science: Universidad de Cuenca, 010202 Cuenca, Ecuador.

Daniel Orellana (D)

Grupo de Investigación LlactaLAB-Ciudades Sustentables, Universidad de Cuenca, 010203 Cuenca, Ecuador.

Ricardo Charry (R)

Faculty of Medical Science: Universidad de Cuenca, 010202 Cuenca, Ecuador.

Andrea Gómez (A)

Escuela de Salud Pública Universidad de Chile, 8380453 Santiago, Chile.

Michael Obimpeh (M)

Family Medicine and Population Health, University of Antwerp, 2610 Antwerp, Belgium.

Veronique Verhoeven (V)

Family Medicine and Population Health, University of Antwerp, 2610 Antwerp, Belgium.

Robert Colebunders (R)

Family Medicine and Population Health, University of Antwerp, 2610 Antwerp, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH